MultiCell Technologies, Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MultiCell Technologies, Inc.

MCET 0.000001000

-90.0%

Jun 6 1:41 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: CENTrader who started this subject	7/19/2004 1:46:44 AM
From: MaxLeverage	Read Replies (1) of 237

In July, 2001 MultiCell Technologies (formerly Multicell Associates) presented a paper in the peer reviewed medical journal, "Artificial Organs". The following paragraph is excerpted: "The development of a human hepatocyte cell line would be applicable also to the pharmaceutical industry as well as for hepatocyte transplantation. An enormous unfulfilled need exists for an in vitro human hepatocyte assay system for high throughput testing of the pharmacological properties and toxicology of newly developed drugs and therapeutic agents. This is due to the widespread recognition that results of rodent in vivo and in vitro models of drug metabolism are not always directly transferable to humans. A differentiated human hepatocyte cell line, especially one which exhibits P450 function, would find immediate and widespread application in pharmacology and toxicology." blackwell-synergy.com Today, three years later, with their patented human hepatocyte cell line being marketed by XenoTech LLC, MultiCell Technologies seems to be making good on those words. See what Pfizer has to say about their cells. exten.com Get some MUsCLe today! multicelltech.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next